Publication details
Letter to Editor: Critical commentary on the study of Siddig et al: Pharmacovigilance of drug-drug interactions: A pharmacokinetic study on the combined oral administration of lurasidone and clozapine in rats by using LC-MS/MS
| Authors | |
|---|---|
| Year of publication | 2025 |
| Type | Article in Periodical |
| Magazine / Source | Journal of Pharmaceutical and Biomedical Analysis |
| MU Faculty or unit | |
| Citation | |
| web | https://www.sciencedirect.com/science/article/pii/S0731708525001402?dgcid=author |
| Doi | https://doi.org/10.1016/j.jpba.2025.116799 |
| Keywords | lurasidone; clozapine ; drug-drug interactions; pharmacovigilance |
| Description | I am writing to address a misinterpretation in the recently published article, "Pharmacovigilance of drug-drug interactions: A pharmacokinetic study on the combined oral administration of lurasidone and clozapine in rats by using LC-MS/MS" by Siddig et al. (https://doi.org/10.1016/j.jpba.2024.116473). The study investigates the pharmacokinetic interactions between lurasidone and clozapine, reporting reductions in the AUC and Cmax of clozapine upon co-administration. However, the authors’ assertion that these findings imply an increased risk of adverse effects from clozapine warrants correction. |